NCT07132996Completed
Spleen Volume Change Predicts 45-Day Mortality in Neurocritical Care: A Prospective Cohort Study
Correlation of Spleen Size and Hematoma Volume With Clinical Course and 45- Day Mortality in Emergency Patients With Hemorrhagic Stroke
Source: ClinicalTrials.gov · Last updated 20 Aug 2025
Brief summary (registry, in English)
This study investigates whether changes in spleen size over 72 hours can help predict the risk of death within 45 days in patients who were admitted to the emergency department with a type of bleeding in the brain called intracerebral hemorrhage. The spleen is a key immune organ that may shrink or enlarge in response to injury. A total of 42 adult patients with confirmed intracerebral hemorrhage were enrolled between March and September 2024 at Ankara Bilkent City Hospital in Turkey. Spleen size and brain bleeding volume were measured by imaging tests at the time of admission and repeated 72 hours later. Patients were followed for 45 days to determine survival status. The main goal of the study was to see if spleen size change (ΔSpleen) is a better predictor of death than brain bleeding volume change (ΔHematoma).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 42 (actual)
- First submitted
- 11 Aug 2025
- Start date
- 15 Mar 2024
- Primary completion date
- 15 Sept 2024
- Lead sponsor
- Ankara City Hospital Bilkent
- Diseases
- Stroke
- NCT number
- NCT07132996
What you commit to
- Study type: Observational
- Participants enrolled: 42
- From 15 Mar 2024 to the primary completion date, 15 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of conditions known to cause splenomegaly (e.g., hematological malignancies, liver cirrhosis, infectious diseases)
Age
- Age under 18 years
Other
- Incomplete or missing imaging data (brain CT or abdominal ultrasound)
- Loss to follow-up or withdrawal of consent before 45 days post-discharge
- Pregnant or breastfeeding women
Who the study is looking for
- Adults aged 18 years and older
- Radiologically confirmed diagnosis of intraparenchymal intracerebral hemorrhage (ICH)
- Underwent baseline and 72-hour follow-up brain CT scans
- Underwent abdominal ultrasound at baseline
- Provided written informed consent prior to participation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ankara Bilkent City Hospital Emergency Medicine Department Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.